These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 14603123)

  • 1. Breast cancer: prevention, prediction, and treatment.
    Mariani SM
    MedGenMed; 2003 Apr; 5(2):24. PubMed ID: 14603123
    [No Abstract]   [Full Text] [Related]  

  • 2. New options in the prevention and treatment of breast carcinoma.
    Galleshaw J
    J Med Assoc Ga; 2003; 92(1):19-22. PubMed ID: 12743901
    [No Abstract]   [Full Text] [Related]  

  • 3. First-generation genomic tests for breast cancer treatment.
    Andre F; Delaloge S
    Lancet Oncol; 2010 Jan; 11(1):6-7. PubMed ID: 20005177
    [No Abstract]   [Full Text] [Related]  

  • 4. Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
    Mouridsen HT
    J Clin Oncol; 2004 Sep; 22(18):3833-4. PubMed ID: 15365083
    [No Abstract]   [Full Text] [Related]  

  • 5. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
    Pohl G; Rudas M; Dietze O; Lax S; Markis E; Pirker R; Zielinski CC; Hausmaninger H; Kubista E; Samonigg H; Jakesz R; Filipits M
    J Clin Oncol; 2003 Oct; 21(19):3594-600. PubMed ID: 14512390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
    Slamon DJ; Press MF
    J Natl Cancer Inst; 2009 May; 101(9):615-8. PubMed ID: 19401550
    [No Abstract]   [Full Text] [Related]  

  • 7. Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
    Puglisi F; de Azambuja E; de Castro G; Demonty G
    J Clin Oncol; 2005 Sep; 23(27):6803-4; author reply 6804-5. PubMed ID: 16170195
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
    Gu M; Ghafari S; Zhao M
    Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracyclines and the tailoring of treatment for early breast cancer.
    Piccart-Gebhart MJ
    N Engl J Med; 2006 May; 354(20):2177-9. PubMed ID: 16707755
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.
    Harris LN; Liotcheva V; Broadwater G; Ramirez MJ; Maimonis P; Anderson S; Everett T; Harpole D; Moore MB; Berry DA; Rizzeri D; Vredenburgh JJ; Bentley RC
    J Clin Oncol; 2001 Mar; 19(6):1698-706. PubMed ID: 11250999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving away from the "one shoe fits all" strategy: the key to future progress in chemotherapy.
    Piccart-Gebhart MJ
    J Clin Oncol; 2005 Mar; 23(8):1611-3. PubMed ID: 15755965
    [No Abstract]   [Full Text] [Related]  

  • 13. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Start tamoxifen after completing chemotherapy, US researchers say.
    McCarthy M
    Lancet; 2002 Jun; 359(9321):1925. PubMed ID: 12057564
    [No Abstract]   [Full Text] [Related]  

  • 15. 94th annual meeting of the American Association for Cancer Research Washington, DC--July 11-14, 2003.
    Lobert S
    Oncol Nurs Forum; 2003; 30(5):741-2. PubMed ID: 12966928
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adjuvant therapy in breast cancer].
    Semiglazov VF
    Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study.
    Namazi S; Rostami-Yalmeh J; Sahebi E; Jaberipour M; Razmkhah M; Hosseini A
    Biomed Pharmacother; 2014 Jun; 68(5):565-71. PubMed ID: 24975086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tamoxifen therapy for breast cancer.
    Jordan VC
    Important Adv Oncol; 1989; ():179-92. PubMed ID: 2651287
    [No Abstract]   [Full Text] [Related]  

  • 19. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.